(PharmaNewsWire.Com, August 03, 2017 ) Alzheimer’s disease (AD) is the most regular cause of progressive dementia in the elderly populace. There has been an exponential increase in the frequency of Alzheimer’s disease cases globally, stressing the need to develop an effectual treatment to cure it. Marketed Drugs lead the global market on the basis of Therapeutics due to a large user base. Under Diagnostics segment, Computed tomography scan segment leads the global Alzheimer’s Disease Therapeutics and Diagnostics market. Absence of alternative imaging tool for brain and neurological diagnostics is one of the crucial reasons for its large share.
According to the report “North America Alzheimer’s Disease Therapeutics and Diagnostics Market ", published by Market Data Forecast, the North America market is projected to reach USD 3.84 billion by 2021, at a CAGR of 4.55% from 2016 to 2021.
Presently, very few therapeutic options are present in the market and none of them offers a complete remedy for this condition. Hence, entry into the market would provide lucrative growth prospects to the industry players.
North America Alzheimer’s Disease Therapeutics and Diagnostics Market: Drivers & Restraints The growth of the Global Alzheimer’s Disease Therapeutics and Diagnostics Market is mainly driven by factors such as growing old age population, rising R&D investment, high frequency of Alzheimer’s and neurodegenerative diseases, and improved life expectancy of the general population. However, factors such as astronomical cost of treatment and lack of proper reimbursement policies are preventing the growth of the market.
North America Alzheimer’s Disease Therapeutics and Diagnostics Market: Overview
Alzheimer’s disease (AD) is the most regular cause of progressive dementia in the elderly populace. The imaging sector was worth $361 million in 2009 and is expected to increase at a nearly 19% compound annual growth rate (CAGR) to reach $852 million in 2014.Marketed Drugs lead the global market on the basis of Therapeutics due to a large user base. Under Diagnostics segment, Computed tomography scan segment leads the global Alzheimer’s Disease Therapeutics and Diagnostics market. Absence of alternative imaging tool for brain and neurological diagnostics is one of the crucial reasons for its large share. Overall, the forecast for Alzheimer's disease, including disease-modifying therapeutics, therapeutics that treat related symptoms, diagnostics and imaging, is set to increase exponentially. This market was worth $8 billion in 2009 and is expected to reach $9.6 billion by 2014, a compound annual growth rate (CAGR) of 3.7%. Diagnostics and biomarkers are expected to increase at a 5-year compound annual growth rate (CAGR) of nearly 20%. This segment was worth $1.2 billion in 2009 and is expected to reach $2.9 billion by 2014.
North America Alzheimer’s Disease Therapeutics and Diagnostics Market: Region-wise Outlook The North America market has been geographically segmented into segmented into US and Canada. According to Alzheimer’s Association, in 2016, an estimated 5.4 million Americans of all ages have Alzheimer's disease. One in nine people aged 65 and above has Alzheimer's disease. By 2050, the number of people aged 65 and above affected with Alzheimer's disease is projected to nearly triple, from 5.2 million to an expected 13.8 million. Increasing R&D activity and a strong pipeline of disease modifying drugs are the crucial factors driving the growth of the market in this region.
Key Questions Answered • What is the current and future North America Alzheimer’s Disease Therapeutics and Diagnostics Market outlook in global? What trends are affecting the North America market?
• What is the competitive landscape and market share of major players in the North America Alzheimer’s Disease Therapeutics and Diagnostics space in North America?
• What are the key, high growth markets that Alzheimer’s Disease Therapeutics and Diagnostics manufacturers should expand into? Which market segments are growing the fastest?
• What are the unmet needs with the Alzheimer’s Disease Therapeutics and Diagnostics currently on the market? How will emerging technologies fulfil these unmet needs?
• What is physician perception and market outlook of Alzheimer’s Disease Therapeutics and Diagnostics Market ?
• How is the Alzheimer's disease therapeutics and diagnostics market evolving?
• What is driving and restraining the Alzheimer's disease therapeutics and diagnostics market growth?
• What are the challenges and barriers that have hindered widespread adoption of North America Alzheimer’s Disease Therapeutics and Diagnostics Market?
• What are the key sustainability strategies adopted by market players ?
North America Alzheimer’s Disease Therapeutics and Diagnostics Market: Key Players
Leading companies have applied tactics such as mergers & acquisitions, collaborations, and joint ventures to gain a strong foothold in the market. The major companies dominating the global Alzheimer’s Disease Therapeutics and Diagnostics market are Abbvie Inc., Pfizer Inc., AC Immune SA, Eisai Co Ltd., Allergan PLC, Novartis AG, Amarantus Bioscience Holdings, H. Lundbeck A/S, Anavex LifeSciences, Avid Radiopharmaceuticals, Forest Laboratories Inc., Axon Neuroscience, Daiichi Sankyo Co, TauRx Therapeutics Ltd, Eli Lilly, F. Hoffmann La Roche AG, Johnson & Johnson, GE Healthcare, Janssen Pharmaceuticals etc.
Reasons to buy North America Alzheimer’s Disease Therapeutics and Diagnostics Market Report:
• Global, regional and country-level analysis and forecasts of the study market; providing Insights on the geographical areas in which this industry is prospering
• Segment-level analysis on basis of product type, application, colour along with market size forecasts and y-o-y estimations to detect key areas of industry growth in detail
• Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
• Study of macro and micro environmental factors that affect the market presented in an extensive strategic analyses section containing PESTLE and Porter’s Five Forces Analyses
• A comprehensive listing of key market players along with company overview, product portfolios, key financial information (subjected to availability), SWOT analysis and Analyst overview to study and sustain the market environment
• Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
• Expertly devised Market Outlook along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
About Market Data Forecast: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
